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Abstract—We have designed and synthesized new types of pyrrole (P)-imidazole (I) polyamide conjugates 1 and 2 possessing a 
suberoylanilide hydroxamic acid (SAHA) moiety that is a strong inhibitor of histone deacetylase (HDAC). SAHA conjugate 2 was 
designed to target the promoter region of the p16 tumor suppressor gene. The DNA binding affinity of SAHA conjugate 2 to its target 
sequence was examined using surface plasmon resonance. HDAC inhibition activity of conjugates 1 and 2 was evaluated using a 
colorimetric assay. The results demonstrated that even though it possesses the relatively large SAHA moiety, conjugate 2 has high DNA 
sequence-specific binding properties and moderate HDAC inhibitory activity in vitro. SAHA conjugate 2 was found to cause 
morphological changes in HeLa cells and to induce selective Histone H3 lysine 9 acetylation. © 2009 Elsevier eScienc. All rights reserved 
Inhibitors of histone deacetylase (HDAC) have recently 
gained prominence as an emerging class of anticancer 
agents.1) HDAC catalyzes the deacetylation of ε-amino 
groups of lysine residues in the N-terminal tails of core 
histones in the nucleosome, resulting in protonated ε-amino 
lysine residues that interact strongly with DNA to give rise 
to an inactive compact chromatin structure.2) In this way, 
HDAC can act as a regulator of gene transcription factors. 
Thus, inhibition of HDAC causes histone hyperacetylation, 
which leads to the disruption of chromatin structure and, as a 
result, the transcriptional activation of epigenetically 
silenced genes, such as tumor suppressor genes in cancer.3) 
Indeed, HDAC inhibitors have been developed as anticancer 
agents. Suberoylanilide hydroxamic acid (SAHA, Figure 1) 
is a potential inhibitor of HDAC that chelates the Zn2+ cation 
at the HDAC active site to induce efficient inhibition.4) 
SAHA has recently been approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of cutaneous 
T-cell lymphoma. Currently, there are over 50 clinical trials 
in progress at the National Institutes of Health (NIH, USA) 
relating to SAHA.5) However, there is currently no system to 
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Figure 1. Chemical structures of suberoylanilide hydroxamic acid (SAHA) 
and trichostatin A (TSA). 
To deliver SAHA to a target region of the genome, we 
used N-methylpyrrole (P) and N-methylimidazole (I) 
polyamides (PI polyamides). PI polyamides bind to the 
minor groove and recognize each of the four Watson–Crick 
base pairs of the double-stranded DNA in a sequence-
specific manner. Antiparallel pairing of the I/P pair 
recognizes the G/C base pair, whereas a P/P pair recognizes 
A/T or T/A base pairs.6) Since the binding constants and 
specificity of PI polyamides are comparable to those of 
transcription factors, the expression of many genes was 
silenced by the binding of PI polyamides to their regulatory 
sequences. Various types of sequence-specific functional 
agents have been developed by conjugation of PI 
polyamides with peptides, alkylating agents and synthetic 
compounds. For example, upregulation of genes has been 
demonstrated by tethering of the PI polyamide to a 
dimerization element or activation domain.7,8) There have 
been no reports of PI polyamide conjugates that can regulate 
histone modification. It is known that the p16 tumor 
suppressor gene is inactivated in many cancers.9) In this 
paper, we report the synthesis and HDAC inhibitory activity 
of PI polyamide–SAHA conjugates 1 and 2 (Figure 2). 
SAHA conjugate 2 was designed to bind to the DNA 
sequence 5′-WGCWGGC-3′, present in the promoter region 
of the tumor suppressor p16 gene.9) 
The synthesis of PI polyamide–SAHA conjugates 1 and 
2 is outlined in Figure 3. A six-ring PI polyamide 4 and ten-
ring PI polyamide 6, with terminal amino groups, were 
prepared by Fmoc solid phase synthesis using a β-alanine-
coupled CLEAR-acid resin. 4-(8-Methoxy-8- 
oxooctanamido) benzoic acid 3 was prepared by coupling of  
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Figure 3. Synthetic scheme for the preparation of PI polyamide–SAHA 
conjugate 1 and 2. (i) N,N-Dimethyl-1,3-propanediamine, 55 °C, overnight. 
(ii) 4-(8-Methoxy-8-oxooctanamido)benzoic acid 3, FDPP, DIEA, DMF, 
room temperature, 6 hours. (iii) NH2OH, H2O, DMF, room temperature, 6 
hours. 
amino benzoic acid with methyl 8-chloro-8-oxooctanoate, 
and converting to an activated ester using pentafluorophenyl 
diphenylphosphinate (FDPP) and N,N-
diisopropylethylamine (DIEA), followed by coupling with 
PI polyamide 4 or 6 to produce 4-(8-methoxy-8-
oxooctanamido) benzoyl conjugated PI polyamide 5 or 7, 
respectively.10,11) The conjugates 1 and 2 were prepared from 
PI polyamides 5 and 7 by amino-de-alkoxylation using a 
solution of hydroxylamine in water/dimethylformamide 
(DMF) (1/1). The conjugates 1 and 2 were confirmed by 
electrospray ionization time-of-flight (ESI–TOF) mass 
spectrometry after purification using reversed-phase HPLC. 
HDAC inhibition by purified conjugates 1 and 2 was 
evaluated in an in vitro assay. 
Sequence-specific binding of PI polyamide–SAHA 
conjugate 2 was evaluated by surface plasmon resonance 
(SPR) experiments. 5′-Biotinylated hairpin DNA 
(oligonucleotide 1, ODN1) containing a single binding site 
(5′–GCWGGC–3′) was prepared (as shown in Figure 4) and 
immobilized on a streptavidin-coated sensor chip. 
Dissociation equilibrium constants (Kd) were obtained by 
fitting the resulting SPR sensorgrams (shown in Figures 5a 
and b) to a theoretical model based on previous studies. The 
Kd values for PI polyamide–SAHA conjugate 2 and its 
precursor polyamide 6 were determined as 3.79 × 10–8 M 
and 3.74 × 10–8 M, respectively. These results demonstrated 
that the PI polyamide–SAHA conjugate has as high an 
affinity for matching DNA as PI polyamide with an NH2 
terminal, and that the SAHA moiety does not inhibit binding 
of PI polyamide to DNA.  
Figure 4. Schematic representation of the binding of PI polyamide–SAHA 
conjugate 2 and PI polyamide 6 to oligonucleotide 1 (ODN1). White circles 
represent pyrroles, black circles imidazoles, diamonds β-alanine and Dp is 
N,N-dimethylamino-3-propanediamine. The binding site is shown in red. 
The inhibition of HDAC activity by PI polyamide–
SAHA conjugates 1 and 2 was examined by a colorimetric 
assay using an acetylated lysine derivative (Biomol 
International) following the manufacturer’s protocol. HDAC 
inhibition was observed at 1000 nM for the PI polyamide–
SAHA conjugates 1 and 2 shown in Figure 6. We confirmed 
that PI polyamide–SAHA conjugates 1 and 2 possess HDAC 
inhibiting activity, and that these activities were lower than 
that of TSA. In addition, the inhibitory activity of conjugate 
2 was slightly lower than that of conjugate 1. These results 
suggest that the HDAC inhibitory activity of the SAHA 
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Figure 5. SPR sensorgrams for the interaction of PI polyamide SAHA 
conjugate 2 (a) and PI polyamide 6 (b) at a concentration of 31.25 nM 
(cyan), 62.5 nM (green), 125 nM (magenta), 250 nM (blue) and 500 nM 
(red), with matching DNA (ODN1). 
Figure 6. HDAC inhibition activities of TSA (white), conjugate 1 (gray), 
and 2 (black). The HDAC activities were determined fluorescently using a 
HDAC Colorimetric Assay/Drug Discovery kit (BIOMOL). Data represent 
the means of three independent experiments; error bars indicate SDs. *P < 
0.05 by unpaired Student’s t-test compared with no drug control (0 nM). 
To evaluate the biological impact of SAHA conjugates, 
HeLa cells were treated with 150 nM SAHA conjugate 2, 
designed to bind to the 5′-WGCWGGC-3′ sequence that 
exists in the promoter region of the p16 tumor suppressor 
gene. As shown in Figure 7, morphological changes of HeLa 
cells were observed after 2 weeks. HeLa cells treated with 
SAHA conjugate 2 became swollen and had larger 
cytoplasms than cells treated with SAHA conjugate 1 
whereas PI polyamide–SAHA conjugate 1, with its short 
recognition sequence, and PI polyamide 1, did not induce 
morphological changes of HeLa cells. 
Figure 7. HeLa cells were cultured in complete Dulbecco's Modified 
Eagle's Medium (SIGMA, St. Louis, MO, USA) supplemented with 10% 
fetal bovine serum in 5% CO2 at 37 °C with following reagents: 150 nM 
SAHA conjugate 1 (a) or conjugate 2 (b) for 2 weeks. Scale bar indicates 
100 µm 
To evaluate whether the SAHA conjugates affect histone 
acetylation of the p16 promoter region, we used a chromatin 
immunoprecipitation (ChIP) assay. The chromatins in HeLa 
cells treated with 150 nM SAHA, SAHA conjugate 1 or 
SAHA conjugate 2, were immunoprecipitated by antibodies 
against acetylated lysine 9 or complete histone H3. The co-
precipitated DNAs were then amplified with the specific 
primer set for the p16 promoter sequence. The amount of 
DNA in the immunoprecipitants using each antibody was 
evaluated. As shown in Figure 8, histone H3 lysine 9 
acetylation in the p16 promoter was twice as high in HeLa 
cells treated with SAHA conjugate 2 than SAHA conjugate 
1. This result suggests that SAHA conjugate 2 has the ability 
to specifically induce acetylation at the target region of 
chromatin where PI polyamide binds. Conjugate 2 was 
designed to target the p16 promoter region. We therefore 
investigated whether conjugate 2 upregulated the expression 
level of p16 and induced G1 cell-cycle arrest in the treated 
cells. Unfortunately, the stable induction of p16 mRNA and 
protein during short-term treatment (∼ 7 days) was not 
observed. FACS analysis indicated that treatment with 150 
nM of conjugate 2 for 7 days resulted in weak G1 arrest in 
cells. A similar effect was also seen after treatment with 
conjugate 2 (supplementary information). Since it is well 
known that SAHA itself induces G1 arrest in cancer cells 
and 2-day treatment with 150 nM SAHA increases sub-G1 
positive cells, this result might be because of the effect of 
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Figure 8. HeLa cells were treated with the indicated reagents (150 nM) for 
seven days. After immunoprecipitation by acetylated (lysine 9) or whole H3 
antibody, the amount of p16 promoter sequence in the co-precipitated 
DNAs was determined by quantitative PCR. We set the ratio of the amount 
of PCR products in acetylated/whole immunoprecipitants in 150 nM 
SAHA-treated cells as 100% in this graph. Data represent the means of 
three independent experiments; error bars indicate SDs. *P < 0.05 by 
unpaired Student’s t test compared with 150 nM SAHA. 
In summary, we synthesized and evaluated PI 
polyamide–SAHA conjugates. PI polyamide–SAHA 
conjugate 2 has high DNA sequence-specific binding ability 
and HDAC inhibitory activity. These results suggest that PI 
polyamide–SAHA conjugates use the PI polyamide moiety 
as a carrier to a specific DNA sequence, where they induce 
acetylation of the chromatin. PI-polyamides with chromatin 
regulators, such as SAHA, are useful molecules to regulate 
chromatin modification at a specific region of the 
chromosome. 
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